Abstract
目的 分析乳腺癌血清可溶性HER-2/neu水平并探讨其临床意义.方法用ELISA方法分析105例乳腺癌患者、24例乳腺良性疾病及30名健康体检者血清可溶性HER-2/neu水平,并用免疫组化(IHC)方法分析乳腺癌组织切片中癌细胞的着色情况.结果乳腺癌患者血清中可溶性HER-2/neu水平与正常对照和良性乳腺疾病相比,差异有统计学意义(P<0.05).随病程进展乳腺癌患者可溶性HER-2/neu的阳性率逐步升高,Ⅲ+Ⅳ期的阳性率(63.3 %) 与Ⅰ期(7.7 %)或Ⅱ期阳性率(14.5 %)相比,差异有统计学意义(P<0.05);发生转移的乳腺癌患者可溶性HER-2/neu的阳性率(37.5 %)与未转移患者(6.1 %)相比,差异有统计学意义(P<0.05).血清HER-2/neu水平与IHC结果有显著正相关(P<0.05).结论检测血清可溶性HER-2/neu水平可弥补免疫组化的不足,在乳腺癌监测随访、疗效观察尤其是用Herceptin治疗后的疗效观察中发挥其独到的作用。
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
